Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew J Yee

Showing results (31-40 of 97) with videos related to

Pageof 10
Sort By:
Blood Cancer Journal|October 27, 2021
Lifestyle considerations in multiple myelomaYael N Shapiro, Jeffrey M Peppercorn, Andrew J Yee, et al.
Skeletal Radiology|June 27, 2016
Abdominal adipose tissue in MGUS and multiple myelomaJoyce Veld, Elizabeth K O'Donnell, Michaela R Reagan, et al.
Transplantation Direct|April 12, 2024
Successful Treatment of Posttransplant Monoclonal Gammopathy-associated C3 Glomerulopathy With Plasma Cell Clone-directed TherapyAyman Al Jurdi, Abraham Cohen Bucay, Leonardo V Riella, et al.
Blood Cancer Journal|April 22, 2026
Validation and refinement of the new Consensus Genomic Staging (CGS) of high-risk multiple myeloma (HRMM) in relapsed and refractory patients treated with BCMA CAR-TJoshua N Gustine, Narsis Attar, Benjamin R Puliafito, et al.
Skeletal Radiology|September 16, 2018
Value of low-dose whole-body CT in the management of patients with multiple myeloma and precursor statesF Joseph Simeone, Joel P Harvey, Andrew J Yee, et al.
Blood|July 20, 2023
Neurologic toxicities following adoptive immunotherapy with BCMA-directed CAR T cellsPhilipp Karschnia, Kevin C Miller, Andrew J Yee, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|October 1, 2023
Radiation therapy as a bridging and salvage strategy in patients with relapsed or refractory multiple myeloma undergoing BCMA-targeted CAR T-cell therapyHazim S Ababneh, Andrew J Yee, Noopur S Raje, et al.
Ebiomedicine|July 3, 2015
Clinical Grade "SNaPshot" Genetic Mutation Profiling in Multiple MyelomaElizabeth O'Donnell, Anuj Mahindra, Andrew J Yee, et al.
JAMA Oncology|August 22, 2018
Assessment of Safety and Immunogenicity of PVX-410 Vaccine With or Without Lenalidomide in Patients With Smoldering Multiple Myeloma: A Nonrandomized Clinical TrialAjay K Nooka, Michael Luhua Wang, Andrew J Yee, et al.
Blood Advances|April 9, 2025
Impact of clonal hematopoiesis on clinical outcomes to BCMA CAR-T in multiple myelomaJoshua N Gustine, Andrew R Branagan, Diana D Cirstea, et al.
Pageof 10

Showing results (31-40 of 97) with videos related to

Sort By:
Pageof 10
Blood Cancer Journal|October 27, 2021
Lifestyle considerations in multiple myelomaYael N Shapiro, Jeffrey M Peppercorn, Andrew J Yee, et al.
Skeletal Radiology|June 27, 2016
Abdominal adipose tissue in MGUS and multiple myelomaJoyce Veld, Elizabeth K O'Donnell, Michaela R Reagan, et al.
Transplantation Direct|April 12, 2024
Successful Treatment of Posttransplant Monoclonal Gammopathy-associated C3 Glomerulopathy With Plasma Cell Clone-directed TherapyAyman Al Jurdi, Abraham Cohen Bucay, Leonardo V Riella, et al.
Blood Cancer Journal|April 22, 2026
Validation and refinement of the new Consensus Genomic Staging (CGS) of high-risk multiple myeloma (HRMM) in relapsed and refractory patients treated with BCMA CAR-TJoshua N Gustine, Narsis Attar, Benjamin R Puliafito, et al.
Skeletal Radiology|September 16, 2018
Value of low-dose whole-body CT in the management of patients with multiple myeloma and precursor statesF Joseph Simeone, Joel P Harvey, Andrew J Yee, et al.
Blood|July 20, 2023
Neurologic toxicities following adoptive immunotherapy with BCMA-directed CAR T cellsPhilipp Karschnia, Kevin C Miller, Andrew J Yee, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|October 1, 2023
Radiation therapy as a bridging and salvage strategy in patients with relapsed or refractory multiple myeloma undergoing BCMA-targeted CAR T-cell therapyHazim S Ababneh, Andrew J Yee, Noopur S Raje, et al.
Ebiomedicine|July 3, 2015
Clinical Grade "SNaPshot" Genetic Mutation Profiling in Multiple MyelomaElizabeth O'Donnell, Anuj Mahindra, Andrew J Yee, et al.
JAMA Oncology|August 22, 2018
Assessment of Safety and Immunogenicity of PVX-410 Vaccine With or Without Lenalidomide in Patients With Smoldering Multiple Myeloma: A Nonrandomized Clinical TrialAjay K Nooka, Michael Luhua Wang, Andrew J Yee, et al.
Blood Advances|April 9, 2025
Impact of clonal hematopoiesis on clinical outcomes to BCMA CAR-T in multiple myelomaJoshua N Gustine, Andrew R Branagan, Diana D Cirstea, et al.
Pageof 10